Centuri (NYSE:CTRI) is a global contract development and manufacturing organization (CDMO) specializing in advanced aseptic processing for both conventional and radiopharmaceutical products. The company offers comprehensive end-to-end solutions that span from early-stage development through commercial supply. Its core capabilities include sterile fill-finish, lyophilization, labeling, secondary packaging, and cold-chain distribution designed to meet the exacting requirements of small molecule, biologic, and solid dose drug products.
With an emphasis on radiolabeled compounds, Centuri provides specialized support for oncology and theranostic pipelines, offering bespoke radiochemistry, quality control testing, and regulatory dossier preparation. Beyond radiopharmaceuticals, the firm serves a broad range of therapeutic areas, delivering process development, analytical method qualification, and stability studies. Centuri’s integrated quality systems, backed by ISO accreditation and adherence to current Good Manufacturing Practices (cGMP), ensure that products are consistently manufactured and tested to the highest standards.
Founded in the mid-1990s, Centuri has evolved from a regional fill-finish provider into a multi-site organization with strategically located facilities in the United States, Europe, and Asia Pacific. Its global footprint enables seamless supply chain management and geographic diversification, supporting clients from biotech start-ups to multinational pharmaceutical companies. The company’s investments in single-use technologies, modular cleanrooms, and digital batch record systems underscore its commitment to operational excellence and scalable capacity.
Centuri’s leadership team combines deep industry experience in pharmaceutical manufacturing, regulatory affairs and business development. This seasoned executive bench drives strategic expansion while maintaining a strong focus on compliance, quality assurance and customer collaboration. Under their guidance, the company continues to bolster its service offerings, pursue targeted partnerships and respond to the evolving demands of the global life sciences sector.
AI Generated. May Contain Errors.
Free CTRI Stock Alerts